In the rapidly evolving world of oligonucleotide therapeutics, researchers are constantly faced with challenges to achieve consistent, high sensitivity results across different sample matrices without the manual labor of traditional methods.
A recent study published in Bioanalysis (Karlsborn et al., 2026) demonstrates a breakthrough with a fully automated extraction workflow using Biotage® Oligo SPE. By moving away from labor-intensive liquid-liquid extraction (LLE), researchers validated a "generic" method capable of handling nine different tissues—including heart, lung, and brain—across three species.
For years, LLE was the go-to for oligonucleotides extraction because it reliably separates oligonucleotides from proteins and lipids. But the resulting extract can still contain hydrophilic compounds that cause signal suppression and require longer LC gradients. As drug pipelines evolve and move into more complex tissues—like the heart, lungs, and brain—the cracks in the LLE method are becoming harder to ignore:
The complexity of tissue homogenates often leads to matrix interference and poor recovery. Biotage® Oligo SPE utilizes a mixed-mode weak anion exchange (WAX) chemistry designed specifically to:
By integrating this method with the Biotage® Extrahera™ automation system, the team didn't just save time; they revolutionized their approach to method validation. The clean extracts provided by the Oligo SPE plates allowed for surrogate matrix calibration, significantly reducing the need for rare blank tissues. This directly supports the reduction principle of the 3Rs (Replacement, Reduction, and Refinement), making it an ethically responsible choice for modern labs.
Whether you are working with ASOs or siRNAs, this delivers high-throughput bioanalysis that is faster, cleaner, and ready for the demands of diverse oligonucleotide pipelines. The Biotage® Oligo SPE toolbox provides the modularity and reliability needed to move from tissue sample to LC-MS/MS ready results in record time.